Quetiapine ('Seroquel'); an effective and well-tolerated atypical antipsychotic

International Journal of Psychiatry in Clinical Practice

Volumn 1, Issue 4, 1997, Pages 231-239

  Meats, Phil ^a  

^a Millbrook Unit   (United Kingdom)

Author keywords

Atypical antipsychotic; Clozapine; Extrapyramidal symptoms; Quetiapine; Schizophrenia

Indexed keywords

EID: 0000581521     PISSN: 13651501     EISSN: None     Source Type: Journal    
DOI: 10.3109/13651509709024734     Document Type: Article

References (33)

1. Davis J, Schaffer C, Killian G et al (1980) Important issues in the drug treatment of schizophrenia. Schizophr Bull 6: 70-87.
2. Brenner H, Dencker S, Goldstein M et al (1990) Defining treatment refractoriness in schizophrenia. Schizophr Bull 16: 551-61.
3. Barnes T, Edwards J (1993) The side-effects of antipsychotic drugs. 1. CNS and neuromuscular effects. In: Antipsychotic drugs and their side-effects, (ed T Barnes), 214-47. Academic Press, London.
4. Barnes T, Edwards J (1993) The side-effects of antipsychotic drugs. II. Effects on other physiological systems. In: Antipsychotic drugs and their side-effects (ed T Barnes). Academic Press, London.
5. Kramer M, Vogel W, Dijohnson C et al (1989) Antidepressants in 'depressed' schizophrenic inpatients. Arch Gen Psychiatry 46: 922-28.
6. Miles C (1977) Conditions predisposing to suicide: a review. J Nerv Ment Dis 164: 231-46.
7. Caldwell C, Gottesman I (1990) Schizophrenics kill themselves too: a review of risk factors for suicide. Schizophr Bull 16: 571-89.
8. Davis J, Metalon L, Watanabe M, Blake L (1994) Depot antipsychotic drugs. Place in therapy. Drugs 47: 741-73.
9. Meltzer H (1992) Treatment of the neuroleptic-nonresponsive schizophrenic patient. Schizophr Bull 18: 515-44.
10. Van Putten T (1974) Why do schizophrenic patients refuse to take their drugs? Arch Gen Psychiatry 31: 67-72.
11. Kane J, Honigfeld G, Singer J et al (1988) Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 35: 789-96.
12. Goldstein J (1995) Pre-clinical pharmacology of new atypical antipsychotics in late stage development. Exp Opin Invest Drugs 4: 291-8.
13. Casey D (1996) 'Seroquel' (quetiapine): preclinical and clinical findings of a new atypical antipsychotic. Exp Opin Invest Drugs 5: 939-57.
14. Goldstein J (1996) Preclinical profile of Seroquel (quetiapine): an atypical antipsychotic with clozapine-like pharmacology. In Schizophrenia: breaking down the barriers (ed S Holliday, R Ancill, G MacEwan), 177-208. Wiley, Chichester.
15. Migler B, Warawa E, Malick J (1993) Seroquel: behavioural effects in conventional and novel tests for atypical antipsychotic drugs. Psychopharmacology 112: 299-307.
16. Robertson G, Matsumura H, Fibiger H (1994) Induction patterns of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. J Pharmacol Exp Ther 271: 1058-66.
17. Meltzer HY (1992) The mechanism of action of clozapine in relation to its clinical advantages: In: Novel antipsychotic drugs (ed HY Meltzer), 1-13 Raven Press, New York.
18. Overall JE, Gorham DR (1962) The brief psychiatric rating scale. Psychiat. Reports 10: 799-812.
19. Kay S, Fiszbein A, Opler L (1987) The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 13: 261-76.
20. Andreason N (1984) Modified scale for the assessment of negative symptoms. NIMH treatment strategies in schizophrenia study. Public Health Administration. US Department of Health and Human Services, ADM 9-102, 9/85, Washington, DC.
21. Guy W, Bonato R (eds) (1970) Manual for the ECDEU Assessment Battery (2nd revised edn) National Institute of Mental Health, Chevy Chase, MD.
22. Borison R, Arvanitis L, Miller B (1996) Group USS ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. J Clin Psychopharmacol 16: 158-69.
23. Small J, Hirsch S, Arvanitis L et al (1997) Quetiapine in patient with schizophrenia: a high- and low-dose double-blind comparison with placebo. Arch Gen Psychiatry 54: 549-57.
24. Arvanitis LA, Miller BG, et al (1997) Multiple fixed dose of 'Seroquel' (Quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with Haloperidol and Placebo. Biol Psychiatry 42: 233-46.
25. Beasley C Jr, Tollefson G, Tran P et al (1996) Olanzapine versus placebo and haloperidol. Acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 14: 111-23.
26. Beasley C Jr, Sanger T, Satterlee W et al (1996) Olanzepine versus placebo: results of a double-blind, fixed-dose olanzepine trial. Psychopharmacology 124: 159-67.
27. van Kammen D, McEvoy J, Targum S et al (1996) A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia. Psychopharmacol 124: 168-75.
28. Peuskens J, Link C (1997) A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatr Scand in press.
29. Fleischhacker W, Link C, Hurst B (1996) ICI 204,636 ('Seroquel') - a putative new antipsychotic: results from Phase III trials. Schizophrenia Res 18: 132.
30. Blackwell B (1976) Treatment adherence. Br J Psychiatry 129: 513-31.
31. Gefvert O, Lindstrom L, Langstrom B et al (1995) Time course for dopamine and serotonin receptor occupancy in the brain of schizophrenic patients following dosing with 150mg 'Seroquel' tid (abstract P-4-65). Eur Neuropsychopharmacol 5: 347.
32. Fleischhacker W, Link C, Horne B (1995) A multicentre, double-blind, randomized comparison of dose and dose regimen of 'Seroquel' in the treatment of patients with schizophrenia. 34th Annual Meeting of the American College of Neuropsychopharmacology, Nashville, Tennessee, 274.
33. Zborowski J, Schmitz P, Sebree T et al (1995) An open-label assessment of the long-term safety of sertindole in the treatment of schizophrenia and other psychotic disorders. Eur Neuropsychopharmacol 5: 348A.